Analysts Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) PT at $50.67

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has received an average recommendation of “Moderate Buy” from the ten brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $50.6667.

Several brokerages have recently issued reports on ORKA. BTIG Research upped their price objective on Oruka Therapeutics from $63.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Barclays assumed coverage on shares of Oruka Therapeutics in a research note on Monday, October 13th. They set an “overweight” rating and a $48.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Thursday, January 22nd. Wedbush lifted their price objective on shares of Oruka Therapeutics from $42.00 to $45.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Finally, Piper Sandler started coverage on shares of Oruka Therapeutics in a research report on Thursday, December 18th. They set an “overweight” rating and a $75.00 target price on the stock.

Insiders Place Their Bets

In related news, insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $31.81, for a total value of $222,670.00. Following the completion of the sale, the insider directly owned 1,518 shares in the company, valued at $48,287.58. This trade represents a 82.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 24.69% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Legal & General Group Plc bought a new stake in shares of Oruka Therapeutics in the 2nd quarter worth about $28,000. Ameritas Investment Partners Inc. bought a new stake in Oruka Therapeutics in the second quarter worth about $31,000. BNP Paribas Financial Markets boosted its position in shares of Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after buying an additional 2,306 shares during the period. PNC Financial Services Group Inc. bought a new position in shares of Oruka Therapeutics during the third quarter valued at approximately $39,000. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Oruka Therapeutics in the third quarter worth approximately $43,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Stock Up 0.2%

Shares of ORKA stock opened at $34.30 on Friday. The stock has a market cap of $1.66 billion, a P/E ratio of -18.05 and a beta of -0.39. Oruka Therapeutics has a 52 week low of $5.49 and a 52 week high of $36.51. The company’s fifty day simple moving average is $31.02 and its two-hundred day simple moving average is $23.77.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.55) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.01. On average, analysts anticipate that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.